724.87
1.00%
-7.33
After Hours:
726.51
1.64
+0.23%
Overview
News
Price History
Option Chain
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly(Eli) & Co stock is currently priced at $724.87, with a 24-hour trading volume of 2.56M.
It has seen a -1.00% decreased in the last 24 hours and a -6.24% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $737.9 pivot point. If it approaches the $723.1 support level, significant changes may occur.
Previous Close:
$732.20
Open:
$725
24h Volume:
2.56M
Market Cap:
$689.18B
Revenue:
$34.12B
Net Income/Loss:
$5.24B
P/E Ratio:
133.76
EPS:
5.4193
Net Cash Flow:
$-3.15B
1W Performance:
-2.83%
1M Performance:
-6.24%
6M Performance:
+23.60%
1Y Performance:
+88.36%
Lilly(Eli) & Co Stock (LLY) Company Profile
Name
Lilly(Eli) & Co
Sector
Industry
Phone
317-276-2000
Address
Lilly Corporate Center, Indianapolis, IN
Lilly(Eli) & Co Stock (LLY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
Nov-09-23 | Initiated | Deutsche Bank | Hold |
Oct-20-23 | Resumed | UBS | Buy |
Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
Jul-26-23 | Reiterated | Citigroup | Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
May-24-23 | Reiterated | BofA Securities | Buy |
May-24-23 | Reiterated | UBS | Buy |
Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-06-23 | Initiated | Jefferies | Hold |
Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
Nov-18-22 | Initiated | Credit Suisse | Outperform |
Sep-22-22 | Upgrade | UBS | Neutral → Buy |
May-23-22 | Initiated | SVB Leerink | Outperform |
Apr-06-22 | Resumed | Morgan Stanley | Overweight |
Mar-10-22 | Initiated | Daiwa Securities | Outperform |
Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
Dec-17-21 | Initiated | Goldman | Neutral |
Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
Dec-16-21 | Reiterated | BofA Securities | Buy |
Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
Jul-27-21 | Resumed | Truist | Buy |
Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Nov-10-20 | Resumed | Bernstein | Mkt Perform |
Sep-29-20 | Initiated | Berenberg | Hold |
Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
Apr-21-20 | Downgrade | UBS | Buy → Neutral |
Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-06-20 | Initiated | Mizuho | Neutral |
Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Oct-17-19 | Resumed | BofA/Merrill | Buy |
May-28-19 | Initiated | Goldman | Buy |
Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
Mar-12-19 | Initiated | JP Morgan | Overweight |
Jan-23-19 | Initiated | UBS | Buy |
Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
Oct-09-18 | Initiated | Guggenheim | Buy |
Oct-01-18 | Reiterated | SunTrust | Buy |
Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly(Eli) & Co Stock (LLY) Latest News
Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics
Zacks Investment Research
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Zacks Investment Research
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
Zacks Investment Research
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Zacks Investment Research
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
Zacks Investment Research
Lilly(Eli) & Co Stock (LLY) Financials Data
Lilly(Eli) & Co (LLY) Revenue 2024
LLY reported a revenue (TTM) of $34.12 billion for the quarter ending December 31, 2023, a +19.56% rise year-over-year.
Lilly(Eli) & Co (LLY) Net Income 2024
LLY net income (TTM) was $5.24 billion for the quarter ending December 31, 2023, a -16.08% decrease year-over-year.
Lilly(Eli) & Co (LLY) Cash Flow 2024
LLY recorded a free cash flow (TTM) of -$3.15 billion for the quarter ending December 31, 2023, a -168.52% decrease year-over-year.
Lilly(Eli) & Co (LLY) Earnings per Share 2024
LLY earnings per share (TTM) was $5.6864 for the quarter ending December 31, 2023, a -16.37% decline year-over-year.
Lilly(Eli) & Co Stock (LLY) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Zakrowski Donald A | SVP, Finance, & CAO |
Mar 11 '24 |
Sale |
753.60 |
750 |
565,200 |
7,880 |
LILLY ENDOWMENT INC | 10% Owner |
Feb 16 '24 |
Sale |
780.99 |
169,684 |
132,521,930 |
98,898,810 |
LILLY ENDOWMENT INC | 10% Owner |
Feb 15 '24 |
Sale |
760.46 |
50,316 |
38,263,417 |
99,068,494 |
LILLY ENDOWMENT INC | 10% Owner |
Feb 09 '24 |
Sale |
740.60 |
206,257 |
152,753,428 |
99,118,810 |
LILLY ENDOWMENT INC | 10% Owner |
Feb 08 '24 |
Sale |
740.06 |
8,743 |
6,470,336 |
99,325,067 |
Van Naarden Jacob | EVP & Pres., Loxo@Lilly |
Feb 01 '24 |
Option Exercise |
0.00 |
3,618 |
0 |
15,463 |
White Anne E. | EVP & Pres, Lilly Neuroscience |
Feb 01 '24 |
Option Exercise |
0.00 |
4,124 |
0 |
62,050 |
Skovronsky Daniel | EVP, CSO & Pres. LRL & LLY Imm |
Feb 01 '24 |
Option Exercise |
0.00 |
9,941 |
0 |
115,262 |
Norton Johna | EVP, Global Quality |
Feb 01 '24 |
Option Exercise |
0.00 |
1,268 |
0 |
31,382 |
Hakim Anat | EVP, GC & Secretary |
Feb 01 '24 |
Option Exercise |
0.00 |
4,442 |
0 |
26,631 |
About Lilly(Eli) & Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; Nektar Therapeutics; NextCure, Inc.; and Dicerna Pharmaceuticals, Inc., as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Cap:
|
Volume (24h):